Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06565507 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oxfendazole in Mild Parenchymal Brain Cysticercosis

StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 30, 2028 to Mar 15, 2030v3 Show 5 more changesShow less
    • Start date: Dec 15, 2024 to Dec 1, 2026
    • Primary endpoint revised
    • Study completion date: Dec 30, 2028 to Dec 15, 2030
    • Eligibility criteria shortened, about 22 words
    • Study description revised
  2. Start date: Sep 30, 2024 to Dec 15, 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare a single and multiple dose regimens of oxfendazole with the standard treatment in patients with mild (one or two lesions) parenchymal brain cysticercosis. The main question it aims to answer is if OXF will enhance clearance of brain parasites and therefore provide greater cysticidal efficacy, with the potential to provide a single-dose therapy for this type of NCC. The study cohort will also allow us to identify early imaging markers that predict lesion resolution, as well as factors associated with residual calcification or focal gliosis after lesion resolution. This study will also provide additional information on the safety of the study interventions.
Trial Details
NCT Number NCT06565507
Lead Sponsor Universidad Peruana Cayetano Heredia
Collaborators: Oxfendazole Development Group
Conditions
(from sponsor)		 Brain Cysticercosis
Related terms Cysticercosis, Neurocysticercosis
Enrollment 544 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov